The requested amendments to the Poisons Standard related to astodrimer sodium are intended to enable the risks and potential benefits of a non-antibiotic vaginal gel for the prevention of recurrent BV, to be communicated to Australian women through labelling and consumer advertising
The amendments would allow advertising of astodrimer for any indication and create new label warning statements for preventative use.
Any Indication could be referring to VIRALEZE™ as well as Vivagel™ BV
The above extracts from TGA would allow for mainstream advertising
Ann: US patent issued for DEP cabazitaxel nanoparticle, page-36
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.5¢ |
Change
-0.003(3.06%) |
Mkt cap ! $39.17M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.5¢ | $12.55K | 130.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 586785 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 56840 | 1 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |